Manufacturers discontinue development of pimavanserin for adjunctive major depressive disorder

This was due to negative results from the phase III CLARITY study, which showed that pimavanserin (an atypical antipsychotic) failed to reduce depressive symptoms compared to placebo (mean reduction of 9.0 vs. 8.1, respectively, in HAMD-17 ).

PharmaTimes